Vinorelbine
- Generic Name
- Vinorelbine
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting .
A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug .
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate .
For the treatment of recurrent or metastatic squamous cell head and neck cancer .
For the treatment of recurrent ovarian cancer .
For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy .
For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus .
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-09-14
- Target Recruit Count
- 30
- Registration Number
- NCT05823623
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 100
- Registration Number
- NCT05764941
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Computed TomographyProcedure: Positron Emission TomographyBiological: PembrolizumabRadiation: Radiation TherapyOther: Transplant Conditioning
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05711628
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- Conditions
- Carcinoma BreastCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 45
- Registration Number
- NCT05603013
- Locations
- 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, China
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 13
- Registration Number
- NCT05583110
- Locations
- 🇪🇸
Hospital Universitario de Jeréz De La Frontera, Cádiz, Andalucía, Spain
🇪🇸Hospital Universitario Reina Sofía, Córdoba, Andalucía, Spain
🇪🇸Hospital Universitario de Jaén, Jaén, Andalucía, Spain
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 632
- Registration Number
- NCT05487391
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai. China, Shanghai, China
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT05296577
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Biological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab Emtansine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 732
- Registration Number
- NCT05104866
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇪🇸
Hospital Galdakao-Usansolo, Bilbao, Spain
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
🇦🇹Pyhrn - Eisenwurzen Klinikum Steyr, Steyr, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.